FDA Form 2253 is the official transmittal document required when pharmaceutical companies submit promotional materials for approved prescription drugs and biologics to the FDA. Title 21 CFR 314.81(b)(3)(i) mandates that drug applicants submit specimens of all advertising and promotional labeling at the time of initial dissemination or publication—failure to comply renders the product misbranded under Section 502(n) of the Federal Food, Drug, and Cosmetic Act.
In September 2025 alone, the FDA’s Office of Prescription Drug Promotion (OPDP) issued approximately 130 warning and untitled letters targeting misleading promotional materials—a historic enforcement surge that signals intensified scrutiny of drug advertising compliance.
Here’s what you’ll learn in this guide:
- 📋 Exactly how to complete each field on Form 2253, with real examples and material type codes
- ⚖️ The legal requirements behind promotional submissions and the consequences of non-compliance
- 💻 Whether to submit electronically via eCTD or through paper—and the mandatory deadlines you cannot miss
- ⚠️ The most common submission errors that trigger FDA rejections and how to avoid them
- ✅ Do’s and Don’ts from regulatory experts to ensure your promotional materials pass FDA review
What Is FDA Form 2253 and Who Must File It?
FDA Form 2253—formally titled “Transmittal of Advertisements and Promotional Labeling for Drugs and Biologics for Human Use”—serves as the cover sheet that accompanies every promotional material submission to the FDA. The form identifies the drug product, lists each promotional piece being submitted, and provides contact information for the responsible regulatory official.
Products Requiring Form 2253 Submissions
The submission requirement applies to the applicant (the holder of the NDA, ANDA, or BLA). If the manufacturer and distributor are different companies, either may submit the materials—but the applicant remains ultimately responsible for compliance under 21 CFR 314.81(b)(3).
What Qualifies as “Promotional Material”?
Promotional labeling encompasses any labeling other than FDA-required labeling that is devised to promote a drug product. This includes brochures, sales aids, direct mail pieces, websites, social media content, television commercials, radio ads, and even scripts for telephone calls. The FDA distinguishes between:
- Advertising: Communications disseminated through broadcast (TV, radio) or print media directed at consumers or healthcare professionals
- Promotional Labeling: Written, printed, audio, or visual matter distributed by or on behalf of the manufacturer that accompanies or references the drug
Both categories require Form 2253 submission at the time of initial use.
The Regulatory Framework: Why Form 2253 Exists
The legal foundation for Form 2253 submissions comes from 21 CFR 314.81(b)(3)(i), which states that applicants “shall submit specimens of mailing pieces and any other labeling or advertising devised for promotion of the drug product at the time of initial dissemination of the labeling and at the time of initial publication of the advertisement.”
Consequences of Non-Compliance
A September 2025 warning letter to pharmaceutical manufacturers stated: “FDA requests [Company] take immediate action to address any violations (including, for example, ceasing and desisting promotional communications that are misleading).” This language reflects the FDA’s heightened enforcement posture.
Step-by-Step Instructions: How to Complete Each Field
The FDA provides official instructions for completing Form 2253. Below is a detailed breakdown of each field with practical guidance.
Box 1: Date Submitted
Enter the date you are sending the form and materials to the FDA. Use the drop-down calendar or MM/DD/YYYY format. This date establishes when you fulfilled your regulatory obligation. For promotional pieces that will be disseminated on a specific date, ensure the submission date is on or before that dissemination date.
Box 2: Application Information
Select the application type from the drop-down menu:
- NDA (New Drug Application)
- ANDA (Abbreviated New Drug Application)
- BLA (Biologics License Application)
- PMA (Premarket Approval Application)
- CDER IND (for authorized Emergency Use Authorization products only)
Enter the six-digit application number. For CBER BLAs, include the supplement number if known.
Single vs. Multiple Products:
Example: A formulary kit containing information about three different drugs from the same manufacturer would require checking “Multiple Products” and attaching a supplementary sheet listing all three application numbers.
Box 3: Proprietary Name
Enter the brand name of the drug product. Include the dosage form if it distinguishes the product from other forms with the same trade name.
Example: “Lipitor Tablets” or “Humira Injection”
Box 4: Established Name
Provide the generic (established) name of the drug. For biological products, include the Product Code Number if known or used.
Example: “atorvastatin calcium” or “adalimumab”
Box 5: Package Insert Date and ID Number
Enter the date and identification number of the most current FDA-approved product labeling. This is critical because promotional materials must be consistent with approved labeling. For paper submissions, include two copies of the package insert.
Box 6: Manufacturer Name and License Number
Provide the manufacturer’s name. For biological product submissions, also include the biologics license number.
Box 7: Advertising/Promotional Labeling Materials
This section requires detailed listing of each promotional piece. Add a new row for each item. Individual components of kits should be listed separately.
Box 7a: Professional or Consumer
Select the primary intended audience. If materials target both audiences, select based on the primary audience and note in Comments (Box 7f) that the piece will be viewed by both.
Box 7b: Material Type Codes
The FDA uses specific codes for material types. Use the exact FDA terminology:
Box 7c: Dissemination/Publication Date
Enter the date of initial dissemination or publication. This is the date the promotional piece first reaches its audience. Use the drop-down calendar or MM/DD/YYYY format.
Box 7d: Material ID Code
Provide your company’s internal identification code for the promotional piece. This helps track materials if the FDA has questions.
Box 7e: Material Description
Write your description of the promotional piece.
Example: “2-page journal advertisement for Healthcare Professional audience promoting efficacy in Type 2 Diabetes”
Box 7f: Comments
Include pertinent information about dissemination methods. Note if a piece is meant to be distributed exclusively with other pieces and identify the accompanying materials.
Boxes 8-12: Contact Information and Certification
- Box 8: Applicant or agent’s return address including country
- Box 9a-c: Telephone, fax, and email of the responsible official
- Box 10: Typed name and title of the responsible official
- Box 11: Signature of responsible official
- Box 12: Date of signature
Box 13: For CBER Products Only
This box applies only to biologics regulated by CBER. Check “Draft” for pre-submission of draft materials or “Final” for postmarketing submissions of final materials. For OPDP submissions (CDER products), do not check either box.
Electronic vs. Paper Submission: Which Method to Use
Since June 24, 2021, the FDA mandates electronic submission via eCTD format for all required Form 2253 postmarketing submissions and accelerated approval pre-submissions. Paper submissions are no longer accepted for these mandatory categories.
Mandatory eCTD Submissions
| Submission Type | Required Format | Submission Gateway |
|---|---|---|
| Form FDA 2253 (postmarketing) | eCTD via ESG | Electronic Submissions Gateway |
| Accelerated Approval Pre-submissions | eCTD via ESG | Electronic Submissions Gateway |
Optional Submission Formats
For non-mandatory submission types (voluntary advisory requests, general correspondence), the FDA accepts:
- eCTD format via ESG
- Non-eCTD electronic format via CDER NextGen Portal
- Paper format via mail or delivery services
eCTD File Placement Requirements
| Document | eCTD Section |
|---|---|
| Form FDA 2253 | Section 1.1 |
| Current Product Labeling | Section 1.14.6 |
| Promotional Materials (clean versions) | Section 1.15.2.1.1 |
| Annotated Materials (optional) | Section 1.15.2.1.2 |
The FDA strongly recommends submitting a test submission to validate your format and ensure systems can receive your files before the actual submission.
Where to Send Submissions
Timing Requirements: When to Submit
The timing of your submission depends on whether your product received standard or accelerated approval.
Standard Approval Products
| Submission Type | Timing Requirement |
|---|---|
| Initial dissemination/publication | At the time of initial use |
| Revised materials | At the time of initial use of revised version |
“At the time” means the submission should reach the FDA on or before the date the promotional piece is first disseminated or published.
Accelerated Approval Products (Subpart H and E)
Products approved under accelerated approval face heightened pre-submission requirements under 21 CFR 314.550 and 21 CFR 601.45.
Example: If you want to use a promotional piece on Day 150 after approval, you must pre-submit it by Day 120 (30 days before use), then submit it again in final form on Form 2253 when you actually disseminate it.
Real-World Scenarios: Action and Consequence Tables
Scenario 1: Launching a New DTC Television Campaign
A pharmaceutical company prepares a 60-second TV commercial for a newly approved diabetes medication.
Scenario 2: Social Media Campaign for an Accelerated Approval Product
A biotech company wants to launch a Twitter campaign for an oncology drug approved under accelerated approval.
Scenario 3: Multiple Product Price List Submission
A manufacturer distributes a formulary price list mentioning five different prescription drugs.
Common Mistakes That Trigger FDA Rejections
The FDA’s Common Errors presentation identifies frequent submission problems. Avoiding these errors saves time and prevents compliance gaps.
General Submission Errors
Form 2253-Specific Errors
Mistakes to Avoid: Promotional Content
Beyond form errors, the FDA scrutinizes the promotional materials themselves. The September 2025 enforcement wave revealed key enforcement priorities.
Do’s and Don’ts for Form 2253 Submissions
Do’s
Don’ts
Pros and Cons of Electronic (eCTD) Submission
Pros
Cons
Key Organizations and Their Roles
Understanding which FDA office reviews your materials prevents misdirected submissions.
FAQs
Does the FDA approve promotional materials before use?
No. Pre-approval is not required except in rare compliance actions or for accelerated approval products, which require pre-submission but not pre-approval.
Can reminder ads skip the brief summary requirement?
Yes. Reminder ads that mention only the drug name without indications or dosage recommendations are exempt from brief summary requirements under 21 CFR 202.1(e)(2)(i).
Are reminder ads allowed for drugs with boxed warnings?
No. Reminder advertisements are prohibited for prescription drugs whose labeling contains a boxed warning relating to a serious hazard.
Do generic drug manufacturers need to submit Form 2253?
Yes. ANDA holders must submit promotional materials at the time of initial dissemination just like NDA holders.
Can I submit Form 2253 by email?
No. Email submission is not accepted. Use eCTD via ESG for mandatory submissions or CDER NextGen Portal/mail for non-mandatory submissions.
How long can I use the word “new” in promotional materials?
Six months. OPDP considers “new” accurate for six months from initial marketing, not from FDA approval date.
Must foreign-language package inserts be submitted in English too?
Yes. Package inserts in other languages must also be submitted in English.
Who submits Form 2253 if manufacturer and distributor differ?
Either may submit, but the applicant (NDA/ANDA/BLA holder) remains ultimately responsible for compliance.
What is “fair balance” in promotional materials?
Fair balance requires that risk information be presented with prominence and readability reasonably comparable to benefit information.
Can I bundle multiple interactive materials in one submission?
Yes. The FDA allows bundling of interactive materials to reduce administrative burden for digital promotions.
What happens if my eCTD submission fails validation?
Resubmission required. Correct the error identified by the validation tool and resubmit with the corrected file.
Are OTC drug promotions subject to Form 2253?
No. Form 2253 applies to prescription drugs and biologics. OTC advertising is regulated by the FTC, though OTC labeling remains under FDA jurisdiction.